E2F3 and neuroblastoma: Furthermore, in TARGET, GSE85047 and E-MTAB-1781 datasets, the expression levels of E2F3 were also higher in neuroblastoma patients with age at diagnosis ≥ 18 months than neuroblastoma patients with age at diagnosis < 18 months (Fig. 4c).